Yahoo! Finance: ARIA News

This Year's Upside Crash & 3 PowerRatings Stocks (TradingMarkets.com)

Mon, 21 Dec 2009 15:44:47 Etc/GMT

Friday Options Update: SVNT, JBLU, ROST, RVSN, MRVL, RYL, ARIA, WLP (at Seeking Alpha)

Fri, 18 Dec 2009 20:48:44 Etc/GMT

Friday Options Update: MRVL, RYL, ARIA, WLP (at Seeking Alpha)

Fri, 18 Dec 2009 18:16:44 Etc/GMT

Ariad rounds out phase 3 cancer study (at bizjournals.com)

Fri, 18 Dec 2009 12:05:12 Etc/GMT

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Thu, 17 Dec 2009 21:31:00 Etc/GMT

ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas (Business Wire)

Thu, 17 Dec 2009 12:35:00 Etc/GMT

CAMBRIDGE, Mass.----ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

Crafting Gifts in a Down Economy (FOX Business Now)

Tue, 15 Dec 2009 23:51:08 Etc/GMT

http://us.news2.yimg.com/us.yimg.com/p/fi/26/44/45.jpg/yfinance/fbc/marketupdate/Crafters_get_together_to_make_presents_12551http://www.foxbusiness.com/http://us.js2.yimg.com/us.js.yimg.com/i/us/fi/pf/images/200711131752/providers/fp_fox_gold.png

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Tue, 15 Dec 2009 21:31:02 Etc/GMT

ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab (Business Wire)

Mon, 14 Dec 2009 12:35:00 Etc/GMT

SAN ANTONIO----ARIAD Pharmaceuticals, Inc. today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab in patients with resistant, metastatic breast cancer.

Biotech Stock Mailbag: Cell Therapeutics (at TheStreet.com)

Fri, 11 Dec 2009 12:00:00 Etc/GMT

JPMorgan, InterOil Options Lure Bulls (at TheStreet.com)

Wed, 9 Dec 2009 20:59:27 Etc/GMT

[$$] Talbots Jumps 14%; Vail Resorts Schusses (at The Wall Street Journal Online)

Wed, 9 Dec 2009 01:39:31 Etc/GMT

Cell Therapeutics on Dilution Watch: BioBuzz (at TheStreet.com)

Tue, 8 Dec 2009 19:16:15 Etc/GMT

Ariad eyes new blood-cancer trial for '10 (at bizjournals.com)

Tue, 8 Dec 2009 16:05:21 Etc/GMT

Ariad, Cephalon Make ASH Splash: BioBuzz (at TheStreet.com)

Tue, 8 Dec 2009 15:45:35 Etc/GMT

Early Market Movers: Yongye International, Geron Corp. (at Fox Business)

Tue, 8 Dec 2009 14:11:25 Etc/GMT

UPDATE - Ariad early-stage cancer treatment shows promise (at Reuters)

Tue, 8 Dec 2009 00:20:23 Etc/GMT

ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (EDGAR Online)

Mon, 7 Dec 2009 22:30:49 Etc/GMT

ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting (Business Wire)

Mon, 7 Dec 2009 22:30:00 Etc/GMT

NEW ORLEANS----ARIAD Pharmaceuticals, Inc. today announced positive clinical data from an ongoing Phase 1 study of its investigational, pan-BCR-ABL inhibitor, AP24534, in patients with advanced hematological cancers.

Hewlett-Packard, Potash Options Lure Bulls (at TheStreet.com)

Wed, 2 Dec 2009 20:34:46 Etc/GMT